KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Intangibles (2023 - 2024)

Historic Change in Intangibles for Vertex Pharmaceuticals (VRTX) over the last 3 years, with Q4 2024 value amounting to $375.4 million.

  • Vertex Pharmaceuticals' Change in Intangibles rose 54724.14% to $375.4 million in Q4 2024 from the same period last year, while for Sep 2025 it was $375.4 million, marking a year-over-year increase of 38943.72%. This contributed to the annual value of $187.7 million for FY2024, which is 22362.07% up from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Change in Intangibles stood at $375.4 million for Q4 2024, which was up 54724.14% from -$7.7 million recorded in Q2 2024.
  • Vertex Pharmaceuticals' Change in Intangibles' 5-year high stood at $375.4 million during Q4 2024, with a 5-year trough of -$180.0 million in Q1 2024.